Global Carcinoembryonic Antigen Market Size, Share, Growth, Industry Trends, Competitive Analysis and Forecast to 2030

Price: 3600/- USD |

The global carcinoembryonic antigen (CEA) market size was accounted for around USD 2.5 billion in 2019 and projected to grow at a significant CAGR of 6.8% market during 2020-2027. The main application of the CEA test is to calculate and observe the protein content in the blood and functionally act as a tumor marker. Its wide application is carried out especially in the diagnosis of rectum and colon cancer. According to surveillance authorities, the normal level of CEA is expected to be 5 nanograms per milliliter (ng/mL) for adult smokers and less than 2.5ng/ml for adult non-smokers. Moreover, high CEA levels in the human body are sometimes the result of a few diseases such as COPD, Crohn’s disease, and cirrhosis. Tumor markers for colorectal cancer are used for initial screening of cancer, staging planning & treatment management, and post-surgery also in order to understand the incidence rate of cancer.

Market Insights:

Carcinoembryonic antigen (CEA) is known as an oncofetal glycoprotein available in the gastrointestinal tract and body fluids of the embryo and fetus. CEA is also present in certain adult gastrointestinal cells, including the mucosal cells of the colon, and in minute amounts in the blood. Market experts suggested that major growth drivers aiding the growth of the CEA market comprises the rising prevalence of cancer, significant growth in the global population base, and increasing demand for minimally invasive diagnostic procedures in cancer. Other factors that assist the overall global market growth are high healthcare expenditure which is fueling the demand for effective diagnostic technologies for oncology and promoting the application of combination biomarkers in oncology treatment.

On the basis of application, the global carcinoembryonic antigen (CEA) market is segmented into colorectal cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, thyroid cancer, and other cancers. In the year 2019, colorectal cancer was observed as the largest CEA market in terms of revenue due to key drivers responsible for its growth are rise in alcohol consumption in the young population, a sedentary lifestyle, and a high intake of saturated fats in all age groups. In addition to this, growing preference for CEA tests in cancer diagnosis and management is anticipated to aid its market growth in the near future.

North America was observed as the largest CEA market in the year 2019 due to the growing demand for minimally invasive cancer diagnosis tests, high public awareness related to early cancer diagnosis, and high accessibility for advanced health care facilities for cancer management. The market experts also suggested that technological advancements followed by novel discoveries of specific antigens and biomarkers are expected to fuel the growth of CEA market testing in this region. Asia-Pacific was the market was observed as the fastest-growing market during the forecast period 2020 – 2027 due to key market driving factors such as the aging population, rising demand, and acceptance for technologically advanced healthcare facilities, supportive governmental policies, and high demand for cost-effective and precise diagnostic procedures.

Market Segment Insights:

The global carcinoembryonic antigen (CEA) market is segmented by applications type. Based on application types, this market is categorized into colorectal cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, thyroid cancer, and other cancers. In the year 2019, the colorectal cancer application segment was observed as the largest segment due to the rising demand for minimally invasive diagnostic procedures, growing geriatric population base, and mounting sedentary lifestyle in the young population. Moreover, high alcohol consumption and lack of physical exercises in the working class are expected to assist the global market of CEA tests during the forecast 2020 – 2027.

Global Carcinoembryonic Antigen (CEA) Market Segmentation:

By  Application Type, 2018–2027 ($ Millon)

  • Ovarian cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Breast Cancer
  • Thyroid Cancer
  • Other Cancers

By Geography, 2018-2027 ($ Millon)

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Regional Insights:

In the year 2019, North America was observed as the leading geographical region in the carcinoembryonic antigen (CEA) market due to key drivers such as rising incidence rates of cancers, availability of accessible and sophisticated healthcare infrastructure, high patient awareness aiding the growth of healthcare expenditure. Asia-Pacific CEA market is expected to achieve the fastest CAGR throughout the forecast period 2020 to 2027. The major factors assisting the exponential growth of this region are the availability of untapped opportunities in cancer diagnosis, incessant improvement in healthcare infrastructure, economic development, and rising patient awareness levels related to early diagnosis.

Market Competition Assessment:

Key players in the global chronic myeloid leukemia (CML) market are: Quest Diagnostics, F. Hoffman LA Roche, Abbott Laboratories, GenWay Biotech Inc., Correlogic Systems, Inc., and Others.

List of Key Companies:

  • Abbott Laboratories
  • Quest Diagnostics
  • Hoffman LA Roche
  • GenWay Biotech Inc.
  • Correlogic Systems, Inc.
  • Others

Key Questions Answered by Carcinoembryonic Antigen Market Report

  • Global carcinoembryonic antigen market forecasts from 2020-2027
  • Regional carcinoembryonic antigen market forecasts from 2020-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
  • Country-level forecasts from 2020-2027 covering 15 major countries from the aforementioned regions
  • Carcinoembryonic Antigen submarket forecasts from 2020-2027 covering application, and geography segments
  • Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to the carcinoembryonic antigen market
  • Analysis of the key factors driving and restraining the growth of the global, regional, and country-level carcinoembryonic antigen markets from 2020-2027
  • Competitive Landscape and market positioning of top 10 players operating in the carcinoembryonic antigen market

Request a full report PDF sample to review @

Table of Content:

Chapter 1 Preface

1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary

2.1 Global Carcinoembryonic Antigen (CEA) Market Portraiture
2.2 Global Carcinoembryonic Antigen (CEA) Market Share, by Application Type, 2019 (US$ Mn)
2.3 Global Carcinoembryonic Antigen (CEA) Market, by Geography, 2019 (Value %)

Chapter 3 Global Carcinoembryonic Antigen (CEA) Market Analysis

3.1 Global Carcinoembryonic Antigen (CEA) Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers Mounting cancer incidences have boosted the demand for research and development in cancer diagnosis technology Minimally invasive cancer diagnosis methods are in high demand In developing countries healthcare expenditure is rising and is expected to assist the demand for effective cancer diagnostic techniques
3.2.2 Challenges Early stage cancer diagnosis is still a challenge for CEA method Regulatory environment in cancer diagnosis is stringent and complicated which hinders the market entry of new companies
3.2.3 Opportunities Technological enhancement in the cancer diagnosis and especially for early cancer diagnosis has high potential in the future
3.3 Attractive Investment Proposition
3.4 Market Share Analysis of Key Manufactures in Carcinoembryonic Antigen (CEA) Market

Chapter 4 Global Carcinoembryonic Antigen (CEA) Market Analysis, by Application Type, 2018-2027 ($ Million)

4.1 Introduction
4.2 Ovarian cancer
4.3 Colorectal Cancer
4.4 Pancreatic Cancer
4.5 Lung Cancer
4.6 Breast Cancer
4.7 Thyroid Cancer
4.8 Other Cancers

Chapter 5 Global Carcinoembryonic Antigen (CEA) Market, by Geography, 2018-2027 ($ Million)

5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin Americ (Brazil, Mexico and Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 6 Company Profiles

6.1 Abbott Laboratories
6.2 Quest Diagnostics
6.3 F. Hoffman LA Roche
6.4 GenWay Biotech Inc.
6.5 Correlogic Systems, Inc.
6.6 Others
Fill the given form to inquiry before buying for Carcinoembryonic Antigen Market Report

(Additional country analysis and conmapny analysis will be added according to the request, we provide free report customization)
(Report covers the impact of COVID-19 on the market)

Request Report Sample
Inquiry Before Buying
Schedule a Call

Select License Type
$ 3600/- Single User License
$ 4600/- Multi User License
$ 5995/- Corporate License

Paypal Certified Payment
For Any Assitance

Why To Choose Us:
  • Markets in over 100+ countries analyzed granularly
  • 35% of our total client are returning clients
  • 1000+ customers globally
  • 100+ paid data sources mined to bring cutting-edge insights
  • 24x5 availability - we are always there when you need us
  • "Free of Cost Report Customization" is available
  • Request a regional report at Best Price

Impacts of COVID-19
COVID-19 Impact on the Carcinoembryonic Antigen Market

Get in Touch

For any coustomized project, contact us here:

Our Clients